179 related articles for article (PubMed ID: 38214896)
1. Pharmacokinetics and pharmacodynamics of antibody-drug conjugates for the treatment of patients with breast cancer.
Cherifi F; Da Silva A; Martins-Branco D; Awada A; Nader-Marta G
Expert Opin Drug Metab Toxicol; 2024; 20(1-2):45-59. PubMed ID: 38214896
[TBL] [Abstract][Full Text] [Related]
2. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
[TBL] [Abstract][Full Text] [Related]
3. [Chinese expert consensus of antibody-drug conjugate toxicity management for breast cancer].
;
Zhonghua Zhong Liu Za Zhi; 2022 Sep; 44(9):913-927. PubMed ID: 36164692
[TBL] [Abstract][Full Text] [Related]
4. Antibody-drug Conjugates for Breast Cancer Treatment.
Sheikh MS; Huang Y
Recent Pat Anticancer Drug Discov; 2022; 18(2):108-113. PubMed ID: 35909271
[TBL] [Abstract][Full Text] [Related]
5. Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2.
Schlam I; Moges R; Morganti S; Tolaney SM; Tarantino P
Crit Rev Oncol Hematol; 2023 Oct; 190():104090. PubMed ID: 37562695
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
[TBL] [Abstract][Full Text] [Related]
7. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer.
von Arx C; De Placido P; Caltavituro A; Di Rienzo R; Buonaiuto R; De Laurentiis M; Arpino G; Puglisi F; Giuliano M; Del Mastro L
Cancer Treat Rev; 2023 Feb; 113():102500. PubMed ID: 36587473
[TBL] [Abstract][Full Text] [Related]
8. Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer.
Najminejad Z; Dehghani F; Mirzaei Y; Mer AH; Saghi SA; Abdolvahab MH; Bagheri N; Meyfour A; Jafari A; Jahandideh S; Gharibi T; Amirkhani Z; Delam H; Mashatan N; Shahsavarani H; Abdollahpour-Alitappeh M
Mol Ther; 2023 Jul; 31(7):1874-1903. PubMed ID: 36950736
[TBL] [Abstract][Full Text] [Related]
9. [Expert consensus on the management of breast cancer antibody-drug conjugates infusion].
Breast Cancer Case Manager Branch of the Chinese Medical Education Association
Zhonghua Yi Xue Za Zhi; 2023 Sep; 103(34):2704-2712. PubMed ID: 37675542
[TBL] [Abstract][Full Text] [Related]
10. Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles.
Fenton MA; Tarantino P; Graff SL
Curr Oncol; 2023 Nov; 30(12):10211-10223. PubMed ID: 38132377
[TBL] [Abstract][Full Text] [Related]
11. Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy.
Shi F; Liu Y; Zhou X; Shen P; Xue R; Zhang M
Drug Deliv; 2022 Dec; 29(1):1335-1344. PubMed ID: 35506447
[TBL] [Abstract][Full Text] [Related]
12. Antibody-Drug Conjugates for Breast Cancer Treatment: Emerging Agents, Targets and Future Directions.
Yang T; Li W; Huang T; Zhou J
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569276
[TBL] [Abstract][Full Text] [Related]
13. Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2.
Abelman RO; Medford A; Spring L; Bardia A
Cancer J; 2022 Nov-Dec 01; 28(6):423-428. PubMed ID: 36383904
[TBL] [Abstract][Full Text] [Related]
14. Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape.
Adams E; Wildiers H; Neven P; Punie K
ESMO Open; 2021 Aug; 6(4):100204. PubMed ID: 34225076
[TBL] [Abstract][Full Text] [Related]
15. Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure.
Antonarelli G; Corti C; Tarantino P; Salimbeni BT; Zagami P; Marra A; Trapani D; Tolaney S; Cortes J; Curigliano G
ESMO Open; 2023 Aug; 8(4):101608. PubMed ID: 37467660
[TBL] [Abstract][Full Text] [Related]
16. Antibody-Drug Conjugates in Triple Negative Breast Cancer.
Keskinkilic M; Sacks R
Clin Breast Cancer; 2024 Apr; 24(3):163-174. PubMed ID: 38341370
[TBL] [Abstract][Full Text] [Related]
17. Future potential targets of antibody-drug conjugates in breast cancer.
Corti C; Boscolo Bielo L; Schianca AC; Salimbeni BT; Criscitiello C; Curigliano G
Breast; 2023 Jun; 69():312-322. PubMed ID: 36996620
[TBL] [Abstract][Full Text] [Related]
18. Antibody-Drug Conjugates in Breast Cancer: Ascent to Destiny and Beyond-A 2023 Review.
Xiao T; Ali S; Mata DGMM; Lohmann AE; Blanchette PS
Curr Oncol; 2023 Jul; 30(7):6447-6461. PubMed ID: 37504334
[TBL] [Abstract][Full Text] [Related]
19. Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer.
Najjar MK; Manore SG; Regua AT; Lo HW
Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360302
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of antibody-drug conjugates in triple-negative and HER-2 positive breast cancer: A systematic review and meta-analysis of clinical trials.
Afzal F; Aiman W; Zahoor H; Bajwa AR; Kazmi SH; Anwar A; Anwar MY; Rashid S; Zubair H; Kashif T; Ashar Ali M
Breast Dis; 2023; 42(1):121-136. PubMed ID: 37125539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
